COVID-19 Detection Kits Remain Key Tools in Pandemic Response
Diagnostic advances bode well for the imminent expansion of the global COVID-19 detection kits market, which is expected to be worth $8 billion by 2027.
Diagnostic advances bode well for the imminent expansion of the global COVID-19 detection kits market, which is expected to be worth $8 billion by 2027.
Healthcare services are expanding their ability to leverage data for use cases such as diagnostics, personalized treatment, imaging analysis, patient trend analysis, outcomes predictions, automation and more.
During the COVID-19 crisis, digital forces like artificial intelligence have assisted the healthcare industry to focus on patient care while achieving improved efficiency during treatments.
GI Genius is based on machine learning and helps clinicians detect lesions in real time during a colonoscopy.
With the accelerated adoption of many new technologies, ECRI’s annual health technology hazards list has been transformed by the COVID-19 pandemic.
A return to normalcy requires us to address the limits of current testing approaches and broadly deploy reliable screening tools that facilitate early detection and encourage more focused testing of those at high-risk of spreading the coronavirus.
The giant leap forward in virtual health is punctuating the need for reliable, clinically accurate technologies to advance how virtual medicine is delivered.
Robotic process automation (RPA) is reducing time spent on repetitive tasks in regulatory affairs and regulatory operations. The next step is artificial intelligence-enhanced RPA, which has the potential to automate more unstructured tasks.
Although the full impact of COVID-19 is uncertain, one sure thing is that industry continues to crave information to help them navigate EU MDR.
Devices in healthcare facilities support mission critical processes. Any issue that degrades network performance can have serious consequences.